Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
URLC10
- Development stage
- Phase 2
- Lead developer
- The University of Tokyo Hospital
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
URLC10 is a peptide antigen derived from the up-regulated lung cancer 10 (LY6K) protein. It is used as a component in synthetic peptide-based therapeutic cancer vaccines designed to stimulate an immune response against tumor cells expressing this antigen. These vaccines are typically formulated with other tumor-associated antigens such as CDCA1 and KOC1, and are administered to patients with cancers like esophageal carcinoma or gastric cancer. The mechanism of action involves immunostimulation—specifically, the activation of cytotoxic T lymphocytes that recognize URLC10-derived peptides presented by HLA-A*2402 or HLA-A*02:01 molecules on tumor cells. Clinical trials have demonstrated safety and some evidence of disease stabilization in advanced cancers refractory to standard therapies.
- Other names
- up-regulated lung cancer 10lymphocyte antigen 6KLY6KLY-6KLY 6K
02
Targets
LY6K (Lymphocyte antigen 6 complex locus protein K)HLA-A*24 (Major histocompatibility complex class I molecule presenting MAGE-A4 peptide)
Beyond the preview
Go deeper on URLC10.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on URLC10.